Resolving spectral overlaps in Anti-Parkinson drug combinations: a green spectrophotometric approach for entacapone determination

解决抗帕金森药物组合中的光谱重叠问题:一种用于恩他卡朋测定的绿色分光光度法

阅读:2

Abstract

A selective and eco-friendly spectrophotometric approach was developed for the quantitative determination of entacapone (ENT) in the presence of its co-formulated drugs carbidopa (CAR) and levodopa (LEV) which exhibit severe spectral overlap. Three simple spectrophotometric methods; direct zero-order, factorized dual wavelength, and ratio subtraction coupled with constant multiplication techniques were optimized to enable effective resolution of the ENT spectrum without the need for prior separation or complex mathematical treatment. The proposed approaches demonstrated high selectivity toward ENT in laboratory-prepared mixtures and pharmaceutical dosage forms confirming the successful minimization of interference from CAR and LEV. The proposed methods showed excellent linearity over the concentration range of 1.5-14.0 µg/mL with a correlation coefficient (r) of 0.9998. The limit of detection (LOD) and limit of quantification (LOQ) were 0.226 µg/mL and 0.685 µg/mL, respectively confirming high sensitivity. The methods were validated according to international guidelines and proved suitable for routine quality control analysis. In addition, the environmental impact of the developed methods was comprehensively evaluated using multiple greenness assessment tools such as Analytical Eco-Scale, NEMI, GAPI, and AGREE tools confirming their excellent sustainability profile. In conclusion, the developed spectrophotometric methods provide a simple, accurate, precise, and green alternative for determining entacapone in the presence of spectral similar compounds without the need for separation or sophisticated instrumentation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。